Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

224
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
224
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

352
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
352
Survival Curves01:18

Survival Curves

427
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
427
Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs01:21

Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs

2.5K
The fundamental mathematical principles, such as calculus and graphs, play crucial roles in analyzing drug movement and determining pharmacokinetic parameters. Differential calculus examines rates of change and helps to determine the dissolution rate of drugs in biofluids, as well as how drug concentrations change over time. For instance, it can help calculate the rate of elimination of a drug from the body based on its concentration-time profile.
On the other hand, integral calculus focuses on...
2.5K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

201
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
201
Decision Making: P-value Method01:09

Decision Making: P-value Method

6.3K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe COVID-19 in Pregnant Versus Nonpregnant Women: Intensive Care Unit Outcomes and Perinatal Risks.

Journal of medical virology·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy : A Target Trial Emulation.

Annals of internal medicine·2026
Same author

Hearing Rehabilitation in Veterans With Severe Hearing Loss: Challenges and Opportunities.

Ear and hearing·2026
Same author

Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, By Chronic Liver Disease Status.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Thirty-Day Readmission After Hospitalisation for Diabetic Foot Ulcer: A Nationwide Analysis.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society·2026

Related Experiment Video

Updated: Nov 9, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K

Net benefit separation and the determination curve: A probabilistic framework for cost-effectiveness estimation.

Andrew J Spieker1, Nicholas Illenberger2, Jason A Roy3

  • 1Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.

Statistical Methods in Medical Research
|April 7, 2021
PubMed
Summary

This study introduces a new probabilistic measure for cost-effectiveness analysis, enhancing how we compare treatment value. It offers a more robust method for evaluating clinical effectiveness and cost, especially with complex data.

Keywords:
Censoringconfoundingcost-effectivenessobservationalpolicy

More Related Videos

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.2K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.3K

Related Experiment Videos

Last Updated: Nov 9, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

6.2K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.3K

Area of Science:

  • Health Economics
  • Biostatistics
  • Clinical Trial Analysis

Background:

  • Comparing treatment value requires integrating clinical effectiveness and cost.
  • Existing methods like net monetary benefit (NMB) and cost-effectiveness acceptability curves (CEACs) have limitations.
  • There's a need for methods that utilize more information from cost-effectiveness data beyond mean differences.

Purpose of the Study:

  • To propose a novel probabilistic measure of cost-effectiveness.
  • To complement existing methods by providing additional insights from cost-effectiveness data.
  • To develop a method suitable for observational data, accounting for confounding and censoring.

Main Methods:

  • Developed a probabilistic measure based on the stochastic ordering of individual net benefit distributions.
  • Utilized simulations to evaluate the finite-sample performance of the proposed measure.
  • Applied the approach to simulated data from an endometrial cancer patient study.

Main Results:

  • The proposed probabilistic measure effectively integrates cost and clinical outcomes.
  • The method accommodates complexities common in observational data, such as confounding and censoring.
  • Demonstrated the approach's utility and insights through simulation and a case study.

Conclusions:

  • The novel probabilistic measure offers a valuable addition to cost-effectiveness analysis.
  • This approach enhances the ability to inform health policy and resource allocation decisions.
  • It provides a more comprehensive understanding of treatment value, especially with real-world data complexities.